Ratings and dated fundamentals
Exact eligible report scores in ranking order. Ratings summarize dated reports, not future returns; report and market dates remain in the table. Showing the first 10 of 97 recorded values; the complete table remains available below.
See the complete ratings and dated fundamentals
Scroll sideways to compare all columns. Select a heading to sort.
| 1 | iRadimed Corporation | IRMD | 4 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $86.31 | $1,103,745,485.43 | 46.02 | 10.37 |
| 2 | Alcon Inc. Ordinary Shares | ALC | 3.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $74.94 | $36,225,996,000 | 36.97 | 1.64 |
| 3 | Boston Scientific Corp. | BSX | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $42.75 | $61,964,980,240.5 | 17.73 | Not reported |
| 4 | CONMED Corporation | CNMD | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $51.5 | $1,534,871,134.5 | 20.9 | 1.45 |
| 5 | DexCom, Inc. | DXCM | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $79.41 | $29,616,032,716.02 | 29.88 | 11.68 |
| 6 | Electromed, Inc. | ELMD | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $27.17 | $227,308,648.71 | 20.11 | 4.21 |
| 7 | GLOBUS MEDICAL INC | GMED | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $71.05 | $9,539,308,989.7 | 17.11 | 1.99 |
| 8 | InMode Ltd. Ordinary Shares | INMD | 3.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $13.33 | $767,063,812.76 | 8.17 | 1.12 |
| 9 | Johnson & Johnson | JNJ | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $276.22 | $664,947,241,674.52 | 41.31 | 8.16 |
| 10 | Merit Medical Systems Inc | MMSI | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $87.23 | $5,226,389,288.12 | 32.64 | 3 |
| 11 | Insulet Corporation | PODD | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $146.51 | $10,163,551,509.93 | 23.7 | 6.44 |
| 12 | The Cooper Companies, Inc. Common Stock | COO | 3 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $62.36 | $11,858,084,133.84 | 20.79 | 1.42 |
| 13 | Inspire Medical Systems, Inc. | INSP | 3 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $63.98 | $1,853,252,293.62 | 18.4 | 2.24 |
| 14 | Pro-Dex Inc New | PDEX | 3 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $63.16 | $202,096,063.16 | 16.8 | 4.1 |
| 15 | Penumbra, Inc. | PEN | 3 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $319.21 | $12,581,465,835.85 | 80.13 | 7.95 |
| 16 | Utah Medical Products Inc | UTMD | 3 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $72.23 | $229,967,174.14 | 21.93 | 1.88 |
| 17 | Viemed Healthcare, Inc. Common Shares | VMD | 3 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $9.13 | $345,963,948.22 | 22.14 | 2.28 |
| 18 | Artivion, Inc. | AORT | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $20.21 | $986,041,292.12 | Not reported | 2.21 |
| 19 | AtriCure, Inc. | ATRC | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $58.54 | $2,980,990,446.82 | 200.29 | 5.59 |
| 20 | Axogen, Inc. Common Stock | AXGN | 2.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $50.02 | $2,987,730,364.3 | Not reported | 6.02 |
| 21 | Baird Medical Investment Holdings Ltd Ordinary Share | BDMD | 2.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $0.09 | $2,825,894.72 | Not reported | 0.09 |
| 22 | Bioventus Inc. Class A Common Stock | BVS | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $10.61 | $892,214,846.8 | 15.57 | 3.06 |
| 23 | Fresenius Medical Care AG | FMS | 2.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $23.4 | $11,477,216,368.8 | 8.52 | 0.68 |
| 24 | Integra LifeSciences Holdings | IART | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $13.42 | $1,044,089,097.92 | 80.23 | 0.98 |
| 25 | ICU Medical Inc | ICUI | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $172.11 | $4,304,488,138.89 | 71.35 | Not reported |
| 26 | Anbio Biotechnology Class A Ordinary Shares | NNNN | 2.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $3.89 | $170,736,768 | 26.66 | 5.66 |
| 27 | Neuropace, Inc. Common Stock | NPCE | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $12.5 | $429,053,425 | Not reported | 36.11 |
| 28 | Envista Holdings Corporation Common stock, $0.01 par value per share | NVST | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $25.17 | $4,035,882,089.46 | 6.37 | Not reported |
| 29 | Pacira BioSciences, Inc. Common Stock | PCRX | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $36.43 | $1,460,648,463.8 | 38.72 | 2.05 |
| 30 | RxSight, Inc. Common Stock | RXST | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $4.54 | $190,358,667.88 | Not reported | 0.75 |
| 31 | SI-BONE, Inc. Common Stock | SIBN | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $24.24 | $1,093,541,228.88 | Not reported | 5.92 |
| 32 | SANUWAVE Health, Inc. Common Stock | SNWV | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.19 | $18,839,056.71 | 1.32 | 6.76 |
| 33 | Sensus Healthcare, Inc | SRTS | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.86 | $47,081,488.74 | Not reported | 1.28 |
| 34 | Xtant Medical Holdings, Inc. | XTNT | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.29 | $40,599,335.62 | Not reported | 1.01 |
| 35 | JIN MEDICAL INTERNATIONAL LTD. Class A Ordinary Shares | ZJYL | 2.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $3.36 | $247,509,118.08 | 207.76 | 8.37 |
| 36 | AngioDynamics, Inc. | ANGO | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $11.73 | $493,298,698.5 | Not reported | 3.01 |
| 37 | Anika Therapeutics Inc | ANIK | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $14.55 | $194,901,804.15 | Not reported | Not reported |
| 38 | Baxter International Inc. | BAX | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $25.79 | $13,342,409,768.52 | Not reported | 2.06 |
| 39 | Beta Bionics, Inc. Common Stock | BBNX | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $15.7 | $853,562,951.9 | Not reported | 2.13 |
| 40 | Bausch Health Companies Inc | BHC | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $8.18 | $3,061,501,736.88 | Not reported | Not reported |
| 41 | Cerus Corp | CERS | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.02 | $407,947,451.68 | Not reported | 5.34 |
| 42 | CVRx, Inc. Common Stock | CVRX | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.87 | $24,744,936.01 | Not reported | 1.79 |
| 43 | Journey Medical Corporation Common Stock | DERM | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $4.47 | $126,163,045.65 | Not reported | 3.93 |
| 44 | Enovis Corporation | ENOV | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $27.16 | $1,566,990,930.96 | Not reported | 1.05 |
| 45 | Inogen Inc | INGN | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $6.03 | $160,026,172.11 | Not reported | 0.92 |
| 46 | OrthoPediatrics Corp. Common Stock | KIDS | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $31.76 | $829,268,717.76 | Not reported | 2.44 |
| 47 | KORU Medical Systems, Inc. Common Stock (DE) | KRMD | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $3.09 | $142,671,177.18 | Not reported | 7.9 |
| 48 | Pulmonx Corporation Common Stock | LUNG | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.56 | $111,489,702.4 | Not reported | 3.26 |
| 49 | Myomo Inc. | MYO | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.21 | $47,925,503.34 | Not reported | 8.22 |
| 50 | InspireMD, Inc. | NSPR | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.7 | $32,356,426.13 | Not reported | 1.03 |
| 51 | Orthofix Medical Inc. Common Stock (DE) | OFIX | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $7.87 | $320,565,624.96 | Not reported | 0.75 |
| 52 | Pulse Biosciences, Inc Common Stock (DE) | PLSE | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $53.29 | $3,919,422,159.96 | Not reported | 21.35 |
| 53 | Profound Medical Corp. Common Stock | PROF | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $7.21 | $264,079,545.24 | Not reported | 6.21 |
| 54 | QuidelOrtho Corporation Common Stock | QDEL | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $10.7 | $734,154,691.6 | Not reported | 0.41 |
| 55 | Sight Sciences, Inc. Common Stock | SGHT | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $10.08 | $560,236,088.16 | Not reported | 11.4 |
| 56 | Sanara MedTech Inc. Common Stock | SMTI | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $31.55 | $289,882,504.25 | Not reported | 36.53 |
| 57 | Neuronetics, Inc. Common Stock | STIM | 2 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $2.15 | $167,115,868.65 | Not reported | 7.46 |
| 58 | TELA Bio, Inc. Common Stock | TELA | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.82 | $36,813,700.74 | Not reported | Not reported |
| 59 | Exagen Inc. Common Stock | XGN | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $5.81 | $140,749,219.59 | Not reported | 11.52 |
| 60 | DENTSPLY SIRONA Inc. | XRAY | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $9.46 | $1,874,533,793.88 | Not reported | 1.38 |
| 61 | Bone Biologics Corp Common Stock | BBLG | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.33 | $1,129,911.6 | Not reported | 0.19 |
| 62 | Biofrontera Inc. Common Stock | BFRI | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.83 | $12,297,753.25 | Not reported | 2.06 |
| 63 | Bluejay Diagnostics, Inc. Common Stock | BJDX | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.35 | $1,165,414.35 | Not reported | 0.12 |
| 64 | BIOMERICA INC | BMRA | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.61 | $7,404,338.48 | Not reported | 2.03 |
| 65 | ClearPoint Neuro, Inc. Common Stock | CLPT | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $8.6 | $275,666,704.8 | Not reported | 10.11 |
| 66 | Cytosorbents Corp. | CTSO | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $4.8 | $15,082,257.6 | Not reported | Not reported |
| 67 | Dare Bioscience, Inc. Common Stock | DARE | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.64 | $9,769,991.78 | Not reported | Not reported |
| 68 | Elutia Inc. Class A Common Stock | ELUT | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.84 | $37,087,801.2 | 0.72 | 2.36 |
| 69 | Establishment Labs Holdings Inc. | ESTA | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $67.02 | $1,997,322,734.82 | Not reported | 92.44 |
| 70 | Femasys Inc. Common Stock | FEMY | 1.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $1.37 | $4,142,834.79 | Not reported | 1.03 |
| 71 | Fractyl Health, Inc. Common Stock | GUTS | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.93 | $12,333,784.91 | Not reported | Not reported |
| 72 | Vyome Holdings, Inc. Common Stock | HIND | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.58 | $11,089,274.24 | Not reported | 1.52 |
| 73 | IceCure Medical Ltd. Ordinary Shares | ICCM | 1.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $0.68 | $3,157,345.95 | Not reported | 0.35 |
| 74 | LENSAR, Inc. Common Stock | LNSR | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $5.45 | $66,957,964.25 | 1.93 | 2.33 |
| 75 | NeuroOne Medical Technologies Corporation Common Stock | NMTC | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.88 | $8,003,965.68 | Not reported | 2.12 |
| 76 | Neuraxis, Inc. | NRXS | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $6.24 | $78,360,453.6 | Not reported | 11.63 |
| 77 | Nuwellis, Inc. Common Stock | NUWE | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $4.58 | $292,332.24 | Not reported | Not reported |
| 78 | enVVeno Medical Corporation Common Stock | NVNO | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $6.73 | $4,676,178.98 | Not reported | 0.28 |
| 79 | Nexalin Technology, Inc. Common Stock | NXL | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.47 | $1,079,784.09 | Not reported | 0.71 |
| 80 | Orchestra BioMed Holdings, Inc. Ordinary Shares | OBIO | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $5.68 | $341,396,678.32 | Not reported | 11.6 |
| 81 | Polyrizon Ltd. Ordinary Shares | PLRZ | 1.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $11.05 | $26,823,931.18 | Not reported | Not reported |
| 82 | Avita Medical, Inc. Common Stock | RCEL | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $16.59 | $518,730,571.45 | Not reported | Not reported |
| 83 | Senseonics Holdings, Inc. Common Stock | SENS | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $8.59 | $454,188,115.27 | Not reported | 5.03 |
| 84 | Sera Prognostics, Inc. Class A Common Stock | SERA | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.19 | $86,394,330.54 | Not reported | 1.65 |
| 85 | Streamex Corp. Common Stock | STEX | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.34 | $39,481,776.36 | Not reported | 0.27 |
| 86 | Talphera, Inc. Common Stock | TLPH | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.05 | $54,501,085.8 | Not reported | 3.78 |
| 87 | TriSalus Life Sciences, Inc. Common Stock | TLSI | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $3.25 | $200,117,450 | Not reported | 30.55 |
| 88 | Treace Medical Concepts, Inc. Common Stock | TMCI | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $4.03 | $264,205,175.91 | Not reported | 4.29 |
| 89 | Tenon Medical, Inc. Common Stock | TNON | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.64 | $15,494.72 | Not reported | Not reported |
| 90 | Virax Biolabs Group Limited Ordinary Shares | VRAX | 1.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $0.79 | $1,065,096 | Not reported | 0.15 |
| 91 | Vivos Therapeutics, Inc. Common Stock | VVOS | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.09 | $1,885,058.76 | Not reported | Not reported |
| 92 | Beyond Air, Inc. Common Stock | XAIR | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.16 | $2,068,482.96 | Not reported | 0.73 |
| 93 | Adagio Medical Holdings, Inc Common Stock | ADGM | 1 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.06 | $1,441,458.79 | Not reported | Not reported |
| 94 | Envoy Medical, Inc. Class A Common Stock | COCH | 1 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $7.15 | $55,373,089.2 | Not reported | Not reported |
| 95 | Solana Company Class A Common Stock (DE) | HSDT | 1 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.93 | $116,685,296.79 | Not reported | 0.69 |
| 96 | ENDRA Life Sciences Inc. Common Stock | NDRA | 1 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $4.73 | $7,094,233.74 | Not reported | 1.12 |
| 97 | Oragenics Inc. | OGEN | 1 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.35 | $1,575,349.79 | Not reported | 0.43 |
No matching rows. Clear the filter to see all records.
97 companies with eligible ratings and dated fundamentals, from 98 eligible companies in this selection.
Inspect a rated peer
Ratings and dated fundamentals
Glaukos Corporation (GKOS): source evidence dated 2026-11-07T12:42:51.530Z.
- Rank
- 1
- Company
- iRadimed Corporation
- Ticker
- IRMD
- Rating / 5
- 4
- Report date
- 2025-12-31
- Fiscal period
- 2025 FY
- Model
- anthropic/claude-haiku-5-5
- Market day
- 2026-11-06
The selected ticker, rating, report date and producing model match the first displayed row. Equal ratings use ticker order.
Which recorded peer has the highest usable rating?
The provider's peer set defines membership. It does not establish identical risk or business models. Read report dates and producing models.
NexusTrade stock ratings and report filters- Median market capitalization
- $202,096,063.16 · 97 / 97 displayed companies
- Median positive P/E (TTM)
- 21.93 · 29 / 97 displayed companies
- Median positive price / book
- 2.24 · 81 / 97 displayed companies
- Largest company by market cap
- Johnson & Johnson (JNJ) · $664,947,241,674.52
- Largest company's share of displayed market cap
- 72.65% · Sum of displayed market caps; not portfolio weights or revenue exposure
Check each median’s included count and each company’s market date. These are unweighted summaries of displayed companies, not a sector index or revenue exposure.
Research GKOS
Open a peer's company view and compare how it actually earns revenue with the anchor company.
Research GKOSKeep reporting dates and units beside the answer, and inspect its original citations.
How these companies are related
Peer membership comes from the same related-company provider used by NexusTrade's stock research. The provider identifies related companies using news coverage and returns data. A related company can be a competitor or a thematic peer; this list does not imply identical products or financial exposure.
Peer membership was fetched 2026-10-12.
The rating determines the order after peer membership is selected. The anchor company is excluded. Companies without an eligible report rating or dated fundamentals are counted in coverage and left out of the ranked table.
What best means in this list
This list was refreshed on 2026-11-07 using existing company reports. The report date in each row is the date of the underlying analysis; refreshing the list does not create a new company report.
Best means the highest stored NexusTrade report ratings within this selection. Ratings use the product's 1-to-5 scale. The list sorts by rating from high to low, with ticker order breaking equal-rating ties. A rating summarizes a report; it does not predict a stock's return.
The peer set comes from the recorded related-company provider. Similarity defines which companies enter this comparison; it does not establish that they have equal business models, risk or expected returns.
What the leading companies do
The first 5 companies below lead the ratings in this snapshot; equal ratings are ordered by ticker. Their company profiles describe different businesses even when they share the Glaukos Corporation (GKOS) selection.
These are company descriptions, not estimates of revenue from this theme. Industry membership does not identify a pure-play business or establish how much sales depend on it. Open the company profile and examine segment disclosures before treating an overlapping classification as equivalent exposure.
iRadimed Corporation (IRMD): 4 / 5
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. The company offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. The company was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Alcon Inc. Ordinary Shares (ALC): 3.5 / 5
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Boston Scientific Corp. (BSX): 3.5 / 5
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
CONMED Corporation (CNMD): 3.5 / 5
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures in the United States and internationally. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, the company offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention; and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.
DexCom, Inc. (DXCM): 3.5 / 5
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Valuation and company size within this selection
These summaries use the 97 displayed companies. Each company retains its own market observation date in the ratings table above. Medians are unweighted; they are not a sector index valuation.
Positive P/E and price-to-book values are summarized separately. Missing, zero and negative values are excluded from those medians, with the included count shown. A lower multiple alone does not establish better value: profitability, growth, debt and business mix can differ.
Show the table · 5 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Median market capitalization | $202,096,063.16 | 97 / 97 displayed companies |
| Median positive P/E (TTM) | 21.93 | 29 / 97 displayed companies |
| Median positive price / book | 2.24 | 81 / 97 displayed companies |
| Largest company by market cap | Johnson & Johnson (JNJ) | $664,947,241,674.52 |
| Largest company's share of displayed market cap | 72.65% | Sum of displayed market caps; not portfolio weights or revenue exposure |
No matching rows. Clear the filter to see all records.
Other business classifications in the list
A company can appear in several product and revenue classifications. These overlapping memberships help identify different business mixes to investigate; they are not verified revenue shares or mutually exclusive subindustries.
Show the table · 5 rows, 2 columns
| Additional classification | Matching displayed companies |
|---|---|
| Healthcare | 97 / 97 |
| Medical Devices | 97 / 97 |
| Hardware | 72 / 97 |
| Technology | 71 / 97 |
| Manufacturing | 63 / 97 |
No matching rows. Clear the filter to see all records.
Dates and coverage
Report dates range from 2025-12-31 to 2025-12-31. Market observations range from 2026-11-06 to 2026-11-06. These dates may differ across companies. Daily closes are not synchronized live quotes.
The selection includes 0 companies without a report, 0 with invalid latest rating metadata, 0 with older reports, 1 with missing required fundamentals and 0 with out-of-date market observations. Missing companies receive no substitute score.
How the ranking is built
The ranking uses the latest stored report at or before the refresh cutoff for each active eligible company. The report date, fiscal year/period and producing model remain visible. The latest invalid score is excluded; an older favorable score does not replace it. Publication policy stock-ratings-v1 accepts report ages up to 550 days and market observations up to 10 calendar days, with a positive close and market capitalization. Optional missing ratios remain not reported.
Report ages can differ substantially, particularly between annual and quarterly reports. Different producing models may also use different judgments. Read the date, fiscal period and model before comparing scores. Private report analysis and account data are not published here.
A refresh reads existing reports and market data. It does not rerun a model or create a new analysis. Compare business fundamentals and your own research constraints alongside the score before making a decision.